一个反复的AML案例,其中包括MYC和MECOM重组
Kevin A Murgas1, Pons Materum2, Luke Z Li3
1Medical Scientist Training Program, Stony Brook University Renaissance School of Medicine, Stony Brook, NY 11794, USA.
Diagnostics (Basel, Switzerland)
|September 27, 2025
概括
复发性急性髓性白血病 (AML) 可以获得新的遗传变化. 这一案例突显了在复发时出现的罕见MYC和MECOM重组,强调了对AML患者的持续监测的必要性.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
背景情况:
- 复发性急性髓性白血病 (AML) 是一个复杂的疾病,其克隆进化和新的基因组异常影响了预后和治疗.
- 复发期间高风险的染色体重组是显著的,但不太了解,特别是罕见和复杂的事件.
研究的目的:
- 报告一个复发的AML病例与罕见的MYC和MECOM重组.
- 强调序列细胞遗传评估在追踪疾病演变中的临床相关性.
主要方法:
- 初步诊断AML的单细胞分化,11q23删除 (KMT2A损失) 和U2AF1突变.
- 用阿扎西蒂丁和维尼托克拉克斯治疗,然后在10个月内复发.
- 在复发时重复细胞遗传分析,显示t(3;8)(q26.2;q24.3) 用MYC和MECOM重组.
主要成果:
- 一名70岁的男性最初被诊断为AML,实现了缓解,但复发.
- 复发的特点是新的MYC和MECOM重组,在初始诊断时没有.
- 这些发现表明基因组不稳定性和克隆进化.
结论:
- 序列细胞遗传和分子分析在复发的AML中至关重要.
- 在复发时出现新的异常,如MYC/MECOM重组,表明疾病正在演变,可能会影响预后和风险分层.
- 持续的细胞遗传监测对于调整AML管理策略至关重要.
关键词:
在 ETV6 上播放.在 EVI1 中.在 KMT2A 中.麦科姆是一个国家.我的世界 MYC这就是U2AF1AF1.急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.染色体的重新排列是什么细胞遗传学分析这是一个复发的复发.更多相关视频
相关概念视频
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Conservative Site-specific Recombination and Phase Variation
6.7K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
6.7K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Adaptive Mechanisms in Cancer Cells
7.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K
Induced Pluripotent Stem Cells
5.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
5.4K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


